MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$960,999
Net Income
-$3,556,415
Net Profit Margin
-370.07%
EPS
-$0.52
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Federal grants
960,999
2,269,837*
493,104
1,371,438
Research and development
3,346,881
3,059,137.5*
2,954,909
1,923,430
General and administrative
1,176,348
1,213,981.5*
1,279,290
1,198,523
Total operating expenses
4,523,229
4,273,119*
4,234,199
3,121,953
Loss from operations
-3,562,230
-2,003,282*
-3,741,095
-1,750,515
Change in fair value of liability classified warrants
-
9,878.5*
998
-853
Interest expense, net
3,923
4,473.5*
6,369
3,160
Other income and expense, net
9,738
15,906.5*
17,338
21,011
Total other income (expense), net
5,815
21,311.5*
11,967
16,998
Net loss
-3,556,415
-1,981,970.5*
-3,729,128
-1,733,517
Deemed dividend related to warrants down round provision
-
-
-
0
Net gain attributable to noncontrolling interests
-
11*
-
-166
Net loss attributable to common stockholders
-3,556,415
-1,981,981.5
-3,729,128
-1,733,351
Basic EPS
-0.52
-0.767
-1.29
-0.79
Diluted EPS
-0.52
-0.767
-1.29
-0.79
Basic Average Shares
6,839,385
2,583,773
2,886,059
2,202,299
Diluted Average Shares
6,839,385
2,583,773
2,886,059
2,202,299
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$3,556,415
Other income and
expense, net
$9,738
Net loss
-$3,556,415
Total other income
(expense), net
$5,815
Interest expense, net
$3,923
Loss from operations
-$3,562,230
Federal grants
$960,999
Total operating
expenses
$4,523,229
Research and development
$3,346,881
General and
administrative
$1,176,348
Buy us a coffee
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)